202 related articles for article (PubMed ID: 34992144)
1. Small-Molecule NSC59984 Induces Mutant p53 Degradation through a ROS-ERK2-MDM2 Axis in Cancer Cells.
Zhang S; Zhou L; El-Deiry WS
Mol Cancer Res; 2022 Apr; 20(4):622-636. PubMed ID: 34992144
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.
Zhang S; Zhou L; Hong B; van den Heuvel AP; Prabhu VV; Warfel NA; Kline CL; Dicker DT; Kopelovich L; El-Deiry WS
Cancer Res; 2015 Sep; 75(18):3842-52. PubMed ID: 26294215
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase.
Melnikova VO; Santamaria AB; Bolshakov SV; Ananthaswamy HN
Oncogene; 2003 Sep; 22(38):5958-66. PubMed ID: 12955074
[TBL] [Abstract][Full Text] [Related]
4. PKB/Akt activation inhibits p53-mediated HIF1A degradation that is independent of MDM2.
Choy MK; Movassagh M; Bennett MR; Foo RS
J Cell Physiol; 2010 Mar; 222(3):635-9. PubMed ID: 19950214
[TBL] [Abstract][Full Text] [Related]
5. Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells.
Li D; Marchenko ND; Schulz R; Fischer V; Velasco-Hernandez T; Talos F; Moll UM
Mol Cancer Res; 2011 May; 9(5):577-88. PubMed ID: 21478269
[TBL] [Abstract][Full Text] [Related]
6. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.
Okamoto K; Kashima K; Pereg Y; Ishida M; Yamazaki S; Nota A; Teunisse A; Migliorini D; Kitabayashi I; Marine JC; Prives C; Shiloh Y; Jochemsen AG; Taya Y
Mol Cell Biol; 2005 Nov; 25(21):9608-20. PubMed ID: 16227609
[TBL] [Abstract][Full Text] [Related]
7. Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.
Frum RA; Love IM; Damle PK; Mukhopadhyay ND; Palit Deb S; Deb S; Grossman SR
Mol Cancer Res; 2016 May; 14(5):423-36. PubMed ID: 26965143
[TBL] [Abstract][Full Text] [Related]
8. Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death.
Koo N; Sharma AK; Narayan S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563397
[TBL] [Abstract][Full Text] [Related]
9. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
[TBL] [Abstract][Full Text] [Related]
10. Mutation at Ser392 specifically sensitizes mutant p53H175 to mdm2-mediated degradation.
Gillotin S; Yap D; Lu X
Cell Cycle; 2010 Apr; 9(7):1390-8. PubMed ID: 20234175
[TBL] [Abstract][Full Text] [Related]
11. Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.
Yang L; Song T; Cheng Q; Chen L; Chen J
Mol Cell Biol; 2019 Feb; 39(4):. PubMed ID: 30455251
[TBL] [Abstract][Full Text] [Related]
12. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
[TBL] [Abstract][Full Text] [Related]
13. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.
Sasaki M; Nie L; Maki CG
J Biol Chem; 2007 May; 282(19):14626-34. PubMed ID: 17363365
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Xu X; Liu Q; Zhang C; Ren S; Xu L; Zhao Z; Dou H; Li P; Zhang X; Gong Y; Shao C
Cell Death Dis; 2019 Mar; 10(4):282. PubMed ID: 30910997
[TBL] [Abstract][Full Text] [Related]
15. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage.
Fu X; Yucer N; Liu S; Li M; Yi P; Mu JJ; Yang T; Chu J; Jung SY; O'Malley BW; Gu W; Qin J; Wang Y
Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4579-84. PubMed ID: 20173098
[TBL] [Abstract][Full Text] [Related]
16. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation.
Fu W; Ma Q; Chen L; Li P; Zhang M; Ramamoorthy S; Nawaz Z; Shimojima T; Wang H; Yang Y; Shen Z; Zhang Y; Zhang X; Nicosia SV; Zhang Y; Pledger JW; Chen J; Bai W
J Biol Chem; 2009 May; 284(21):13987-4000. PubMed ID: 19321440
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin in Combination with MDM2 Inhibition Downregulates Rad51 Recombinase in a Bimodal Manner to Inhibit Homologous Recombination and Augment Tumor Cell Kill.
Xie X; He G; Siddik ZH
Mol Pharmacol; 2020 Apr; 97(4):237-249. PubMed ID: 32063580
[TBL] [Abstract][Full Text] [Related]
18. Oridonin induces Mdm2-p60 to promote p53-mediated apoptosis and cell cycle arrest in neuroblastoma.
Zhu HQ; Zhang C; Guo ZY; Yang JM; Guo JH; Chen C; Yao QH; Liu F; Zhang QW; Gao FH
Cancer Med; 2019 Sep; 8(11):5313-5326. PubMed ID: 31339234
[TBL] [Abstract][Full Text] [Related]
19. Hypomethylation-Linked Activation of PLCE1 Impedes Autophagy and Promotes Tumorigenesis through MDM2-Mediated Ubiquitination and Destabilization of p53.
Chen Y; Xin H; Peng H; Shi Q; Li M; Yu J; Tian Y; Han X; Chen X; Zheng Y; Li J; Yang Z; Yang L; Hu J; Huang X; Liu Z; Huang X; Zhou H; Cui X; Li F
Cancer Res; 2020 Jun; 80(11):2175-2189. PubMed ID: 32066565
[TBL] [Abstract][Full Text] [Related]
20. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
